Merck (MRK) EBT Margin (2009 - 2026)
Merck (MRK) reported EBT Margin of 21.49% for Q1 2026, down 5950.0% year-over-year from 0.37% in Q1 2025, and down 203.06% quarter-over-quarter from 20.85% in Q4 2025.
Merck (MRK) EBT Margin (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of EBT Margin data on file, last reported at 21.49% in Q1 2026.
- EBT Margin for Q1 2026 came in at 21.49%, down 5950.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 17.74% (down 1382.0% YoY), and the FY2025 annual result was 32.41%, up 134.0% from the prior year.
- EBT Margin retreated to 21.49% in Q1 2026 per MRK's latest filing, from 20.85% in the prior quarter.
- Over five years, EBT Margin peaked at 39.04% in Q3 2025 and troughed at 35.25% in Q2 2023.
- A 5-year average of 20.84% and a median of 26.69% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2024: EBT Margin tumbled 6600 bps in 2023, then jumped 7253 bps in 2024.
- A 5-year view of EBT Margin shows it stood at 25.4% in 2022, then tumbled by 155 bps to 13.98% in 2023, then jumped by 291 bps to 26.69% in 2024, then decreased by 22 bps to 20.85% in 2025, then sank by 203 bps to 21.49% in 2026.
- Business Quant data shows MRK's EBT Margin at 21.49% in Q1 2026, 20.85% in Q4 2025, and 39.04% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 28.10% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 44.70% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 24.89% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 6.93% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 135.53% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 28.20% |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.49% |
| Dec 31, 2025 | 20.85% |
| Sep 30, 2025 | 39.04% |
| Jun 30, 2025 | 31.63% |
| Mar 31, 2025 | 38.01% |
| Dec 31, 2024 | 26.69% |
| Sep 30, 2024 | 24.55% |
| Jun 30, 2024 | 37.28% |
| Mar 31, 2024 | 35.94% |
| Dec 31, 2023 | -13.98% |
| Sep 30, 2023 | 35.21% |
| Jun 30, 2023 | -35.25% |
| Mar 31, 2023 | 25.20% |
| Dec 31, 2022 | 25.40% |
| Sep 30, 2022 | 23.95% |
| Jun 30, 2022 | 30.75% |
| Mar 31, 2022 | 30.57% |
| Dec 31, 2021 | 28.91% |
| Sep 30, 2021 | 40.03% |
| Jun 30, 2021 | 15.06% |